65,437 trials
Lung Diseases, Interstitial
Primary: Absolute Change From Baseline in Forced Vital Capacity (FVC) in Milliliters [mL] at Week 52 — -165.77; -84.64; -98.59 Milliliters (mL) — p=<0.0001
Interstitial Cystitis and Bladder Pain Syndrome
Primary: Patient Global Assessment (PGA) — 90.1 percentage of participants (%)
Ovarian Cancer · Peritoneal Cancer · Fallopian Tube Cancer
Primary: Objective Response Rate (ORR) Assessed by Investigator Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1]) — 51.9 percentage of participants
Localized Prostate Carcinoma · Prostate Adenocarcinoma
Primary: Effects of the Intervention on ADT-induced Changes in Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) — 4.5; 42.7 percentage change
Obesity
Primary: Weight — 98.2; 93.5; 95.3; 91.6 kg
Clinical Stage IV Cutaneous Melanoma AJCC v8 · Metastatic Malignant Neoplasm in the Brain · Metastatic Melanoma
Primary: Clinical Benefit Rate (CBR) in PD-1 naïve Patients — 68.4 percentage of participants
Healthy
Primary: Part 1: Area Under the Concentration-time Curve of Dabigatran in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞) — 725.25; 971.67…
Fall Patients · Delirium · Quality of Life
Primary: Health Related Quality of Life (HRQoL) Using the Patient-Reported Outcomes Measurement Information System (PROMIS) Global Health Scale v1.2 — -0.73; -0.33 T score — p=0.61
Adult Growth Hormone Deficiency · Endocrine System Diseases · Hormone Deficiency
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs and TEAE Leading to Study Discontinuation — 48; 52; 45; 7 Participants
Schizophrenia
Primary: Double-blind Period: Change in the Positive and Negative Syndrome Scale (PANSS) Total Score From Baseline to Week 8 — -12.17; -21.91; -23.44; -21.93 units on a scale…
Healthy Participants
Primary: Areas Under the Serum Concentration Versus Time Curve Extrapolated to Infinity (AUC0-∞) — 2321566.8; 2358855.5 h*ng/mL
Labor Long
Primary: Time to Delivery — 1041.8; 971.1 minutes
PTSD
Primary: Change in Amygdala Activation as Measured by Functional Magnetic Resonance Imaging (fMRI) Blood Oxygen Level Dependent (BOLD) Signal — 0.534; -0.0037 beta weights
Schizophrenia Schizoaffective · Schizophrenia
Primary: Change of Resting-state Functional Connectivity (rsFC) by Active and Sham rTMS — 0.018; 0.007 z score of functional connectivity
Aging · Alzheimer Disease · Age-related Cognitive Decline
Primary: Change in Plasma Amyloid Beta (Aβ) Levels — 0.343; -0.371; 0.381; -0.332 Z-score — p=0.817